EDARAVON: YON AMIOTROFIK KASALLIGINI DAVOLASHDA YANGICHA YONDASHUV
##article.subject##:
Yon amiotrofik skleroz, edaravon, oksidlovchi shikastlanish, ta'sir mexanizmi##article.abstract##
Yon amiotrofik skleroz (YAS) -markaziy asab tizimining progressiv kasalligi bo'lib, yuqori va pastki motorli neyronlarning shikastlanishi va og'ir nogironlik va boshlanishidan 3-5 yil o'tgach o'limga olib keladi (1). 2017 yilgacha bu kasallikning davosida ishlatiladigan yagona dori vositasi riluzol edi. YAS bilan og'rigan bemorlar uchun tasdiqlangan dori -darmonlar, taxminan 3-5 oylik hayotni uzaytirib beradi. (2) 2017 yilda FDA ( Food and drug administration) YASni davolash uchun yana bir dori - edaravonni (savdo nomlari: radikut, radikava, aron, seravon) tasdiqladi.(3) Preparat kuchli antioksidant bo'lib, lipid peroksidlanish mahsulotlarini (LPM) va gidroksil radikallarini yo'q qiladi. Riluzolda bo'lgani kabi, edaravonning aniq ta'sir mexanizmi aniq emas. Preparat YASda xavf ostida bo'lgan neyronlar va glia (asab to'qimasidagi qo'shimcha hujayralar) ning oksidlovchi shikastlanishini yumshatadi, deb ishoniladi. Yaponiyada preparatning III bosqich klinik tadqiqotida YAS rivojlanishining dastlabki bosqichiga ega 137 bemor ishtirok etdi. Edaravon bu bemorlarda motor funktsiyasining yomonlashuvini bostirishda samarali ekanligi isbotlangan. AQShda edaravon YAS bilan kasallangan barcha bemorlarni davolash uchun tasdiqlangan bo'lsa -da, uni kasallikning dastlabki bosqichida, debyut qilingan kundan boshlab 2 yil ichida, 80% dan ortiq majburiy hayotiy quvvati bo'lgan bemorlarda qo'llash tavsiya qilingan. (4). YAS bilan og'rigan bemorlarning keng populyatsiyasida edaravonning samaradorligi to'g'risida ma'lumotlar yo'q. Ushbu preparatning hayot uzunligini uzaytirish darajasini baholash bilan uning samaradorligini o'rganish davom etmoqda. Yuqoridagilarni hisobga olgan holda, YAS terapiyasiga yangi yondashuvlarni ishlab chiqish dolzarb muammo bo'lib qolmoqda.
Библиографические ссылки
I. S.Bakulin, A.V. Worms, 2017.
Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic
lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330:585-91.
Miyaji Y., Yoshimura S., Sakai N. et al. Effect of edaravone on favorable outcome in patients with acute cerebral large vessel occlusion: subanalysis of RESCUE-Japan registry. Neurol Med Chir (Tokyo) 2015;55(3):241–7. DOI: 2176/nmc. ra.20140219. PMID: 25739433.
Abe K., Aoki M., Tsuji S. et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurology 2017;16(7):505–12. DOI: 10.1016/S14744422(17)30115-1. PMID: 28522181.
Zarei S, Car r K, Reiley L, Diaz K, Guerra O, Altamirano PF,et al. A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int. 2015;6:171. (https://www.accessdata.fda.gov/drugsatfda_docs/ label/2017/209176lbl.pdf
Suponeva N. A., Piradov M. A. 2013, Zavalishin I. A., Piradov M.A., Boyko A.N. 2014].
Chio A.G., Traynor B.J, Logroscino G., et al. 2013.
Parakh S, Spencer DM, Halloran MA, Soo KY, Atkin JD.Redox regulation in amyotrophic lateral sclerosis. Oxid Med Cell Longev. 2013;2013:408681.
. D’Amico E, Factor-Litvak P, Santella RM, Mitsumoto H.Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med. 2013;65:509–27.
Murata T, Ohtsuka C, Terayama Y. Increased mitochondrial oxidative damage in patients with sporadic amyotrophic lateral sclerosis. J Neurol Sci. 2008;267:66–9.
Mitsumoto H, Santella RM, Liu X, Bogdanov M, Zipprich J, Wu HC, et al. Oxidative stress biomarkers in sporadic ALS. Amyotroph Lateral Scler. 2008;9:177–83.
Bogdanov M, Brown RH, Matson W, Smar t R, Hayden D,O’Donnell H, et al. Increased oxidative damage to DNA inALS patients. Free Radic Biol Med. 2000;29:652–8.
Blasco H, Garcon G, Patin F, Veyrat-Durebex C, Boyer J, Devos D, et al. Panel of oxidative stress and inflammatory biomarkers in ALS: a pilot study. Can J Neurol Sci.
. Simpson EP, Henr y YK, Henkel JS, Smith RG, Appel SH. Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden. Neurology. 2004;62:1758–65.
Baillet A, Chanteperdrix V, Trocme´ C, Casez P, Garrel C, Besson G. The role of oxidative stress in amyotrophic lateral sclerosis and Parkinson’s disease. Neurochem Res. 2010;35:1530–7
Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C.Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis. Ann Neurol. 1999;46:129–31.
Beal MF, Ferrante RJ, Browne SE, Matthews RT, Kowall NW, Brown RH Jr. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol. 1997;42:644–54.
LoGerfo A, Chico L, Borg ia L, Petrozzi L, Rocchi A,D’Amelio A, et al. Lack of association between nuclear factor er ythroid-derived 2-like 2 promoter gene polymorphisms and oxidative stress biomarkers in amyotrophic lateral sclerosis patients. Oxid Med Cell Longev.2014;2014:432626.
Pasquinelli A, Chico L, Pasquali L, Bisordi C, Lo Gerfo A, Fabbrin i M, et al. Gly482Ser PGC-1 a gene polymorphism and exercise-related oxidative stress in amyotrophic lateral sclerosis patients. Front Cell Neurosci. 2016;10:102.
The Edaravone Acute Brain Infarction Study Group (Chair:Otomo E). Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters.Cerebrovasc Dis. 2003;15:222–9.
National Institute of Neurological Disorders and Stroke. Amyotrophic Lateral Sclerosis (ALS) fact sheet. National Institutes of Health. Updated June 20, 2020. Accessed May 20, 2021. https://www.ninds.nih.gov/ Disorders/Patient-Caregiver-Education/Fact-Sheets/Amyotrophic-Lateral-Sclerosis-ALS-Fact-Sheet
American Academy of Neurology. AAN summary of evidence-based guideline for clinicians: The care of the patient with amyotrophic lateral sclerosis: drug, nutritional and respiratory therapies. American Academy of Neurology. Updated January 11, 2020. Accessed May 20, 2021. https://www.aan.com/ Guidelines/home/GuidelineDetail/370
Miller RG, Brooks BR, Swain-Eng RJ, et al. Quality improvement in neurology: Amyotrophic lateral sclerosis quality measures: Report of the quality measurement and reporting subcommittee of the American Academy of Neurology. Neurology. 2013;81(24):2136-40. doi:10.1212/01.wnl.0000437305.37850.f9
Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1227-33. doi:10.1212/WNL.0b013e3181bc01a4
Yamamoto Y, Kuwahara T, Watanabe K, Watanabe K. Antioxidant activity of 3-methyl-1-phenyl-2-pyrazolin-5-one. Redox Rep. 1996;2:333–8.
Abe S, Kirima K, Tsuchiya K, Okamoto M, Hasegawa T, Houchi H, et al. The reaction rate of edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186)) with hydroxyl radical. Chem Pharm Bull. 2004;52:186–91.
Kamogawa E, Sueishi Y. A multiple free-radical scavenging
(MULTIS) study on the antioxidant capacity of a neuroprotective drug, edaravone as compared with uric acid,glutathione, and trolox. Bioorg Med Chem Lett.2014;24:1376–9.
Fujisawa A, Yamamoto Y. Edaravone, a potent free radicalscavenger, reacts with peroxynitrite to produce predominantly 4-NO-edaravone. Redox Rep. 2016;21:98–103.
